NCT06753981 Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
| NCT ID | NCT06753981 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qianfoshan Hospital |
| Condition | Arterial Pulmonary Hypertension (PAH) |
| Study Type | OBSERVATIONAL |
| Enrollment | 48 participants |
| Start Date | 2024-12-10 |
| Primary Completion | 2026-11-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 48 participants in total. It began in 2024-12-10 with a primary completion date of 2026-11-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a multicenter, prospective, observational study aimed at investigating the efficacy and safety of triple targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are receiving initial treatment. The prognosis of arterial pulmonary hypertension is explored.
Eligibility Criteria
Inclusion Criteria: * Consent and sign the informed consent form * Non-low-risk PAH treatment-naive patients Exclusion Criteria: * Positive acute vascular response test for idiopathic/hereditary/drug-related arterial pulmonary hypertension * Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) with arterial pulmonary * Pregnant or lactating women * Suffering from mental illness or cognitive impairment * PAH patients with concurrent malignant tumors * Patients with moderate to severe hepatic impairment, renal impairment, and severe anemia * Currently participating in other interventional clinical studies * Key clinical data is incomplete, or the investigator considers that the patient has other factors that make them unsuitable for this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06753981 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Arterial Pulmonary Hypertension (PAH). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06753981 currently recruiting?
Yes, NCT06753981 is actively recruiting participants. Contact the research team at 224138908@qq.com for enrollment information.
Where is the NCT06753981 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT06753981 clinical trial?
NCT06753981 is sponsored by Qianfoshan Hospital. The trial plans to enroll 48 participants.